AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAPLACIZUMAB AND IMMUNOSUPPRESSIVE THERAPY WITHOUT FIRST-LINE THERAPEUTIC PLASMA EXCHANGE IN ADULTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA

Registry ID

EFC16521

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

SANOFI-AVENTIS CANADA INC

Start date

2023-07-25

Last update

2022-06-27

Conditions

• THROMBOTIC THROMBOCYTOPENIC PURPURA

Related clinical trials

• "A PHASE 2, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF RADAMTS-13 (SHP655) ADMINISTERED IN ADDITION TO STANDARD OF CARE (SOC) TREATMENT."

View on source registry